S&P 500 7,419.02 â–ŧ 92.33 (-1.23%) DOW 51,473.85 â–ŧ 525.82 (-1.01%) NASDAQ 26,019.46 â–ŧ 356.89 (-1.35%) US Markets Closed â€ĸ 06:18 PM ET

UNCY

Unicycive Therapeutics, Inc.

Price Chart
Latest Quote

$7.05

-0.12 (-1.67%)
Current Price
Previous Close $7.17
Open $7.25
Day High $7.36
Day Low $6.96
Volume 1,137,162
Fetched: 2026-06-17T22:18:16
Stock Information
Shares Outstanding 27.39M
Total Debt $815K
Cash Equivalents $54.59M
Net Income $-39.95M
Sector Healthcare
Industry Biotechnology
Market Cap $193.12M
EPS (TTM) $-2.25
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$137.67M
Income$-39.95M
Book/sh$1.49
Cash/sh$1.99
Employees21
Financial Ratios
Quick Ratio2.06
Current Ratio2.40
Debt/Eq2.16
Returns & Margins
ROA-40.56%
ROE-163.14%
Ownership
Insider Ownership2.36%
Institutional Ownership37.68%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E1.17
P/B4.72
Analyst Data
Recommendationnone
Target Price$41.30
Technical Indicators
SMA20$7.31
SMA50$7.43
SMA200$6.13
RSI50.40
ATR0.5610
Shares Float24.28M
Short Float10.88%
Short Ratio4.25
Rel Volume1.28
Performance History
Week-8.32%
Month-13.50%
Quarter+4.29%
6 Months+19.90%
YTD+21.55%
Year-6.50%
3 Years-58.53%
10 Years-85.90%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-17 $7.05 1,137,162
2026-06-16 $7.17 1,109,500
2026-06-15 $7.12 1,037,800
2026-06-12 $7.25 943,600
2026-06-11 $7.69 682,400
2026-06-10 $7.69 1,030,200
2026-06-09 $7.27 874,200
2026-06-08 $6.66 1,043,500
2026-06-05 $6.92 1,201,300
2026-06-04 $7.43 664,900
2026-06-03 $7.20 514,000
2026-06-02 $7.23 902,200
2026-06-01 $7.60 937,100
2026-05-29 $7.38 608,300
2026-05-28 $7.02 743,500
2026-05-27 $7.07 1,013,100
2026-05-26 $7.06 1,637,400
2026-05-22 $8.08 588,900
2026-05-21 $7.63 598,300
2026-05-20 $7.74 557,100
2026-05-19 $7.73 598,200
2026-05-18 $8.15 488,000
About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $675,000 $951,000
Operating Revenue $0 $0 $675,000 $951,000
Expenses
Interest Expense $71,000 $71,000 $82,000 $6,000
Total Expenses $29,517,000 $32,117,000 $21,449,000 $19,003,000
Other Income Expense $2,021,000 $-5,802,000 $-10,303,000 -
Net Non Operating Interest Income Expense $941,000 $1,190,000 $533,000 $-6,000
Interest Expense Non Operating $71,000 $71,000 $82,000 $6,000
Operating Expense $29,517,000 $32,117,000 $21,449,000 $19,003,000
General And Administrative Expense $20,396,000 $12,103,000 $8,547,000 $6,567,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Net Interest Income $941,000 $1,190,000 $533,000 $-6,000
Interest Income $1,012,000 $1,261,000 $615,000 $0
Normalized Income $-28,576,000 $-30,927,000 $-20,241,000 $-18,058,000
Net Income From Continuing And Discontinued Operation $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Total Operating Income As Reported $-29,517,000 $-32,117,000 $-20,774,000 $-18,052,000
Net Income Common Stockholders $-26,555,000 $-37,824,000 $-31,411,000 $-18,058,000
Net Income $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Net Income Including Noncontrolling Interests $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Net Income Continuous Operations $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Pretax Income $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Interest Income Non Operating $1,012,000 $1,261,000 $615,000 $0
Operating Income $-29,517,000 $-32,117,000 $-20,774,000 $-18,052,000
Special Income Charges - - - $0
Per Share
Diluted EPS $-1.67 $-5.65 $-12.80 $-12.00
Basic EPS $-1.67 $-5.65 $-12.80 $-12.00
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-27,933,000 $-30,428,000 $-19,875,000 $-17,891,000
Total Unusual Items $2,021,000 $-5,802,000 $-10,303,000 $0
Total Unusual Items Excluding Goodwill $2,021,000 $-5,802,000 $-10,303,000 $0
Reconciled Depreciation $572,000 $428,000 $284,000 $161,000
EBITDA (Bullshit earnings) $-25,912,000 $-36,230,000 $-30,178,000 $-17,891,000
EBIT $-26,484,000 $-36,658,000 $-30,462,000 $-18,052,000
Diluted Average Shares $15,886,876 $6,698,513 $2,453,930 $1,505,704
Basic Average Shares $15,886,876 $6,698,513 $2,453,930 $1,505,704
Diluted NI Availto Com Stockholders $-26,555,000 $-37,824,000 $-31,411,000 $-18,058,000
Gain On Sale Of Security $2,021,000 $-5,802,000 $-10,303,000 -
Research And Development $9,121,000 $20,014,000 $12,902,000 $12,436,000
Selling General And Administration $20,396,000 $12,103,000 $8,547,000 $6,567,000
Other Gand A $20,396,000 $12,103,000 $8,547,000 $6,567,000
Preferred Stock Dividends - $1,095,000 $867,000 -
Other Special Charges - - - -
Fetched: 2026-06-17
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $30,197,000 $7,431,000 $-3,809,000 $-466,000
Total Assets $49,135,000 $31,668,000 $14,191,000 $2,818,000
Total Non Current Assets $174,000 $720,000 $792,000 $174,000
Current Assets $48,961,000 $30,948,000 $13,399,000 $2,644,000
Other Current Assets $1,171,000 $939,000 $325,000 $159,000
Prepaid Assets $6,521,000 $3,867,000 $3,373,000 $2,030,000
Cash Cash Equivalents And Short Term Investments $41,269,000 $26,142,000 $9,701,000 $455,000
Cash And Cash Equivalents $29,198,000 $26,142,000 $9,701,000 $455,000
Cash Financial $29,198,000 $26,142,000 $9,701,000 $455,000
Current Deferred Assets - - - -
Debt
Total Debt $199,000 $773,000 $811,000 $201,000
Long Term Debt And Capital Lease Obligation $0 $117,000 $466,000 $0
Current Debt And Capital Lease Obligation $199,000 $656,000 $345,000 $201,000
Current Debt $82,000 $92,000 $18,000 $46,000
Liabilities
Total Liabilities Net Minority Interest $18,938,000 $24,237,000 $18,000,000 $3,284,000
Total Non Current Liabilities Net Minority Interest $0 $117,000 $466,000 $0
Current Liabilities $18,938,000 $24,120,000 $17,534,000 $3,284,000
Other Current Liabilities $16,915,000 $18,936,000 $13,134,000 -
Payables And Accrued Expenses $1,824,000 $4,528,000 $4,055,000 $3,083,000
Payables $301,000 $966,000 $821,000 $846,000
Accounts Payable $301,000 $966,000 $821,000 $846,000
Equity
Common Stock Equity $30,197,000 $7,431,000 $-3,809,000 $-466,000
Total Equity Gross Minority Interest $30,197,000 $7,431,000 $-3,809,000 $-466,000
Stockholders Equity $30,197,000 $7,431,000 $-3,809,000 $-466,000
Gains Losses Not Affecting Retained Earnings $-1,000 $0 - -
Other Equity Adjustments $-1,000 - - -
Retained Earnings $-127,825,000 $-101,270,000 $-64,541,000 $-33,997,000
Other
Ordinary Shares Number $22,114,245 $11,384,236 $3,475,604 $1,523,165
Share Issued $22,114,245 $11,384,236 $3,475,604 $1,523,165
Tangible Book Value $30,197,000 $7,431,000 $-3,809,000 $-466,000
Invested Capital $30,279,000 $7,523,000 $-3,791,000 $-420,000
Working Capital $30,023,000 $6,828,000 $-4,135,000 $-640,000
Capital Lease Obligations $117,000 $681,000 $793,000 $155,000
Total Capitalization $30,197,000 $7,431,000 $-3,809,000 $-466,000
Additional Paid In Capital $158,001,000 $108,690,000 $60,697,000 $33,516,000
Capital Stock $22,000 $11,000 $35,000 $15,000
Common Stock $22,000 $11,000 $35,000 $15,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $0 $117,000 $466,000 $0
Current Capital Lease Obligation $117,000 $564,000 $327,000 $155,000
Line Of Credit $82,000 $92,000 $18,000 $46,000
Current Accrued Expenses $1,523,000 $3,562,000 $3,234,000 $2,237,000
Net PPE $174,000 $720,000 $792,000 $174,000
Accumulated Depreciation $-72,000 $-39,000 $-16,000 $-7,000
Gross PPE $246,000 $759,000 $808,000 $181,000
Leases $65,000 $49,000 $21,000 $15,000
Other Properties $26,000 $26,000 - -
Machinery Furniture Equipment $47,000 $39,000 $21,000 $14,000
Buildings And Improvements $108,000 $645,000 $766,000 $152,000
Properties $0 $0 $0 $0
Other Short Term Investments $12,071,000 $0 - -
Construction In Progress - $10,000 $0 -
Dueto Related Parties Current - - - -
Fetched: 2026-06-17
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-31,341,000 $-28,647,000 $-18,295,000 $-15,653,000
Operating Activities
Operating Cash Flow $-31,317,000 $-28,575,000 $-18,283,000 $-15,651,000
Cash Flow From Continuing Operating Activities $-31,317,000 $-28,576,000 $-18,283,000 $-15,651,000
Operating Gains Losses $-2,021,000 $5,802,000 $10,303,000 -
Investing Activities
Capital Expenditure $-24,000 $-72,000 $-12,000 $-2,000
Investing Cash Flow $-12,095,000 $-72,000 $-12,000 $-2,000
Cash Flow From Continuing Investing Activities $-12,095,000 $-72,000 $-12,000 $-2,000
Financing Activities
Issuance Of Capital Stock $46,582,000 $50,683,000 $30,190,000 $11,000
Financing Cash Flow $46,468,000 $45,088,000 $27,541,000 $-471,000
Cash Flow From Continuing Financing Activities $46,468,000 $45,088,000 $27,541,000 $-471,000
Net Other Financing Charges $-1,610,000 $-4,500,000 $-2,649,000 $-482,000
Cash Dividends Paid $0 $-1,095,000 $0 -
Net Preferred Stock Issuance $0 $50,000,000 $30,190,000 $0
Preferred Stock Issuance $0 $50,000,000 $30,190,000 $0
Net Common Stock Issuance $46,582,000 $683,000 $0 $11,000
Common Stock Issuance $46,582,000 $683,000 $0 $11,000
Other
Interest Paid Supplemental Data $0 $12,000 $24,000 $6,000
End Cash Position $29,198,000 $26,142,000 $9,701,000 $455,000
Beginning Cash Position $26,142,000 $9,701,000 $455,000 $16,579,000
Changes In Cash $3,056,000 $16,441,000 $9,246,000 $-16,124,000
Proceeds From Stock Option Exercised $1,496,000 $0 - $0
Net Investment Purchase And Sale $-12,071,000 $0 - -
Purchase Of Investment $-12,071,000 $0 - -
Net PPE Purchase And Sale $-24,000 $-72,000 $-12,000 $-2,000
Purchase Of PPE $-24,000 $-72,000 $-12,000 $-2,000
Change In Working Capital $-5,954,000 $-427,000 $-93,000 $1,178,000
Change In Other Current Liabilities $-565,000 $-397,000 $-252,000 $-151,000
Change In Payables And Accrued Expense $-2,505,000 $790,000 $1,276,000 $1,267,000
Change In Payable $-2,505,000 $790,000 $1,276,000 $1,267,000
Change In Account Payable $-2,505,000 $790,000 $1,276,000 $1,267,000
Change In Prepaid Assets $-2,884,000 $-820,000 $-1,117,000 $62,000
Stock Based Compensation $2,641,000 $2,350,000 $1,767,000 $1,047,000
Depreciation Amortization Depletion $572,000 $428,000 $284,000 $161,000
Depreciation And Amortization $572,000 $428,000 $284,000 $161,000
Depreciation $572,000 $428,000 $284,000 $161,000
Gain Loss On Investment Securities $-2,021,000 $5,802,000 $10,303,000 -
Net Income From Continuing Operations $-26,555,000 $-36,729,000 $-30,544,000 $-18,058,000
Income Tax Paid Supplemental Data - $0 $0 $0
Other Non Cash Items - $1,000 - $21,000
Repayment Of Debt - - - $0
Issuance Of Debt - - - $0
Net Issuance Payments Of Debt - - - $0
Net Long Term Debt Issuance - - - $0
Long Term Debt Payments - - - $0
Long Term Debt Issuance - - - $0
Pension And Employee Benefit Expense - - - $0
Fetched: 2026-06-17